VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stake in Eli Lilly and Company $LLY

VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in Eli Lilly and Company (NYSE:LLY) by 21.2% during the fourth quarter, HoldingsChannel reports. The fund owned 95,204 shares of the company’s stock after buying an additional 16,640 shares during the period. Eli Lilly and Company comprises approximately 0.6% of VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings, making the stock its 27th largest position. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Eli Lilly and Company were worth $102,314,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the last quarter. 10Elms LLP grew its stake in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares during the last quarter. Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth $33,000. Finally, Hopwood Financial Services Inc. grew its stake in shares of Eli Lilly and Company by 113.6% in the third quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock worth $36,000 after acquiring an additional 25 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a research report on Tuesday, February 10th. Berenberg Bank increased their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price objective for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Finally, TD Cowen increased their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,218.33.

Eli Lilly and Company Trading Up 2.4%

Shares of NYSE:LLY opened at $990.11 on Wednesday. The stock has a market capitalization of $932.43 billion, a price-to-earnings ratio of 35.17, a PEG ratio of 1.05 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock’s 50-day simple moving average is $939.93 and its two-hundred day simple moving average is $994.31. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-phase trial results showed Foundayo and lower-dose Zepbound helped patients maintain most of their prior weight loss after switching from higher-dose injectable therapies, strengthening Lilly’s obesity franchise. Article: Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss…
• Positive Sentiment: Reuters reported that Lilly launched its Alzheimer’s drug Donanemab, sold as Lormalzi, in India, expanding access to another potential growth product outside the U.S. Article: Eli Lilly launches Alzheimer’s drug Donanemab in India
• Positive Sentiment: Commentary highlighted Lilly as the dominant player in the fast-growing GLP-1 market, which may keep investor sentiment elevated around its obesity and diabetes pipeline. Article: GLP-1 Wars: Winners & Losers
• Positive Sentiment: Barclays raised its price target on LLY to $1,400 from $1,350 and kept an Overweight rating, signaling continued confidence in long-term growth. Article: Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.